Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib as First-Line Treatment in Primary HLH in Children
NCT05762640Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05762640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762640.